New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
07:32 EDTDYAXDyax shares should be bought, says RBC Capital
After meeting with Dyax's management, RBC Capital thinks sales of the company's Kalbitor drug may surpass expectations in Q2, while the company could start talking on its Q2 conference call about new indications for the drug that investors haven't considered. The firm believes that the company has a number of potential positive catalysts from upcoming clinical trials, and it keeps a $15 price target and Outperform rating on the shares.
News For DYAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
07:10 EDTDYAXDyax sees FY15 Kalbitor net sales $60M-$70M
Subscribe for More Information
07:08 EDTDYAXDyax reports Q4 EPS (2c), consensus (4c)
Reports Q4 revenue $26M, consensus $19.9M.
February 20, 2015
07:08 EDTDYAXAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use